JP2003501387A5 - - Google Patents

Download PDF

Info

Publication number
JP2003501387A5
JP2003501387A5 JP2001501216A JP2001501216A JP2003501387A5 JP 2003501387 A5 JP2003501387 A5 JP 2003501387A5 JP 2001501216 A JP2001501216 A JP 2001501216A JP 2001501216 A JP2001501216 A JP 2001501216A JP 2003501387 A5 JP2003501387 A5 JP 2003501387A5
Authority
JP
Japan
Prior art keywords
methylphenidate
treatment
threo
racemic
respond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001501216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501387A (ja
Filing date
Publication date
Priority claimed from GBGB9913458.7A external-priority patent/GB9913458D0/en
Application filed filed Critical
Publication of JP2003501387A publication Critical patent/JP2003501387A/ja
Publication of JP2003501387A5 publication Critical patent/JP2003501387A5/ja
Pending legal-status Critical Current

Links

JP2001501216A 1999-06-09 2000-06-08 注意欠損活動亢進障害の治療のためのｄ−トレオ−メチルフェニデートの治療的使用 Pending JP2003501387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9913458.7A GB9913458D0 (en) 1999-06-09 1999-06-09 The therapeutic use of d-threo-methylphenidate
GB9913458.7 1999-06-09
PCT/GB2000/002234 WO2000074680A1 (en) 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder

Publications (2)

Publication Number Publication Date
JP2003501387A JP2003501387A (ja) 2003-01-14
JP2003501387A5 true JP2003501387A5 (enExample) 2007-07-05

Family

ID=10855048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001501216A Pending JP2003501387A (ja) 1999-06-09 2000-06-08 注意欠損活動亢進障害の治療のためのｄ−トレオ−メチルフェニデートの治療的使用

Country Status (9)

Country Link
EP (1) EP1185268B1 (enExample)
JP (1) JP2003501387A (enExample)
AT (1) ATE302006T1 (enExample)
AU (1) AU766748B2 (enExample)
CA (1) CA2376215A1 (enExample)
DE (1) DE60022033T2 (enExample)
ES (1) ES2243273T3 (enExample)
GB (1) GB9913458D0 (enExample)
WO (1) WO2000074680A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
KR101318806B1 (ko) 2005-01-20 2013-10-16 인스티튜트 포 몰리큘러 메디신, 인코포레이티드 메틸페니데이트 유도체 및 그 용도
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
CN108348775B (zh) 2015-09-15 2021-07-02 普瑞西斯生物学研究有限责任公司 芬坎法明的前药

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514451D0 (en) * 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
MX9805870A (enExample) * 1996-01-22 1999-01-31
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate

Similar Documents

Publication Publication Date Title
USD492502S1 (en) Bed
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
EP1979324A4 (en) IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE DISORDER, MORBUS ALZHEIMER, NEURODEGENERATION AND DEMENTIA.
JP2003520232A5 (enExample)
WO2006060314A3 (en) Generation of replication competent viruses for therapeutic use
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
JP2004525194A5 (enExample)
USD499910S1 (en) Bed footboard
EP1651195A4 (en) PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
DK1643999T3 (da) Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
JP2003501387A5 (enExample)
EP1177792A3 (en) Dopamine D4 Ligands for the treatment of novelty-seeking disorders
JP2003522147A5 (enExample)
EE200300060A (et) Polaarsete rühmadega perfluoroalküülrühma sisaldavad kompleksid, nende valmistamismeetod ja kasutamine
USD509977S1 (en) Bed footboard
USD509976S1 (en) Bed headboard
USD507714S1 (en) Bed footboard
USD528331S1 (en) Bed footboard
JP2004508063A5 (enExample)
JP2003516751A5 (enExample)
JP2004508333A5 (enExample)
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl